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The aim of this study was to investigate technical and
analytical performance of the first automated thyro-
globulin (Tg) assay (DPC-Immulite®; Diagnostic Prod-
ucts Corporation, Los Angeles, USA). In imprecision
studies using several human serum pools ranging
from 21 to 58 replicates, a coefficient of variation of 9.0
% was obtained at a mean Tg concentration of 0.84
ng/ml and of 6.1 % at a Tg concentration of 62.1 ng/ml.
In a method comparison with a non-automated assay
(BRAHMS LUMItest Tg®, BRAHMS, Berlin, Germany)
using 383 sera of 303 patients with thyroid carcinoma,
regression analysis according to Passing and Bablock
yielded in the following equation:
Immulite Tg=1.6 x BRAHMS Tg – 0.1 ng/ml      
(Pearson’s r=0.979). 
Sera obtained from 59 patients with thyroid carcinoma
enabled comparative follow-up studies; in all cases
qualitative agreement was found with regard to in-
crease or decrease of serum Tg; in eight cases, how-
ever, Tg was detected with the Immulite assay but not
with the BRAHMS assay. Further follow-up proved the
presence of thyroid tissue in these patients. From
these and further methodological data (dilution linear-
ity, interference studies, carry-over study, high-dose
hook properties, and short report time) it is concluded
that the DPC-Immulite Tg assay meets the require-
ments of routine diagnostic use.
Key words: Thyroglobulin; Immunoassay; Thyroid car-
cinoma.
Introduction
Thyroglobulin (Tg), a heterogeneous iodoglycoprotein
with a molecular weight of about 660 kDa, is a main
constituent of the vesicular thyroid colloid. It is synthe-
sized under regulation of thyrotropin exclusively by the
thyroid gland and is the precursor of thyroxine and tri-
iodothyronine. The main indication for determination
of serum Tg is the follow-up of patients with differen-
tiated thyroid carcinoma after thyroablative surgery
and radioiodine therapy; measurable and increasing
serum Tg concentrations are an early and reliable indi-
cator of persistent or recurrent disease with important
prognostic significance (1-4). Beside this, serum Tg is
useful in the diagnosis of neonatal hypothyroidism. In
hyperthyroid adults undetectable serum Tg suggests
thyrotoxicosis factitia.
In conventional manual radioimmunoassys (RIAs)
and radioactivity-free Tg assays, incubation steps of
several hours are required and results are obtained
only after up to 24 h; with the Immulite Tg assay (Diag-
nostic Products Corporation, Los Angeles, CA, USA),
now the first Tg assay implemented on a random ac-
cess multichannel analyser is commercially available.
With this luminescence-enhanced immunoenzymo-
metric assay system results are obtained within 70
min. The aim of our study was to investigate the analyt-
ical performance of this assay.
The most important performance goal for a Tg assay
is a high precision at low serum Tg concentrations (4,
5). As detectable serum Tg usually results in further im-
aging work-up or even therapy (6, 7), this lowest con-
centration range is of far greater clinical significance
for Tg assays than for most other tumor markers; there-
fore our evaluation was planned to focus particularly
on the assay imprecision at the lowest concentration
range.
Materials and Methods
Main assay characteristics of the Immulite Tg assay and the
BRAHMS LUMItest Tg assay (BRAHMS, Berlin, Germany) that
was used for method comparisons are given in Table 1. The Im-
mulite Tg assay is calibrated against the reference material
CRM 457 (human Tg of glandular origin) provided by the Euro-
pean Community Bureau of References (Brussels, Belgium),
whereas for the BRAHMS assay an in-house preparation is
used. In the Immulite assay the only manual handling step is
the transfer of samples from primary vessels into system assay
cups and the positioning of test units together with the respec-
tive sample in a loading chain. Results can be uploaded to a la-
boratory data system. Chemiluminescence reaction is used as
principle of detection; luminogenic substrate (Lumigen, ada-
mantyldioxetane phosphate), reacts – catalyzed by antibody-
coupled alkaline phosphatase – to form an unstable intermedi-
ate which gives sustained emission of light that is quantified by
a photomultiplier. In contrast the BRAHMS LUMItest Tg assay
uses an acridinium ester as luminogen that only yields a single
light emission. The latter assay is performed predominantly
manually, though the luminogenic reaction and quantification
is run in a semiautomated way by a chain luminometer (Bert-
hold, Wildbad, Germany). In a previous study (unpublished
data) a coefficient of variation of 20 % was found at a Tg con-
centration of 1 ng/ml with this assay and therefore quantitative
results are reported only above this concentration.
Assay studies were performed in a preroutine evaluation
period (September to December 1997) and further evaluation
data were obtained after beginning of the routine use of the
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Immulite Tg assay from March until June 1998. The evalua-
tion and the routine use were performed by trained techni-
cians according to the manufacturer’s recommendations and
the German guidelines for quality assurance.
Imprecision
For imprecision studies two human serum pools in a low and
one pool in a high analyte concentration range were prepared,
aliquoted after equilibration for 24 h, and stored at –20 °C un-
til analysis. The “high pool” contained 180 IU/l anti-Tg anti-
bodies (DPC Anti-Tg Immulite assay, Diagnostic Products Cor-
poration; normal < 100 IU/l) whereas the low pools did not
contain such antibodies. Interassay imprecision was deter-
mined by 21 independent measurements over 26 days; ac-
cording to the manufacturer’s recommendations a recalibra-
tion was performed after 14 days. Additionally, imprecision
data from the two controls included in the reagent kit and a
further human serum pool used for quality control during the
routine use of the assay were assessed; these samples were
stored at 4 °C for up to seven days between measurements
and analyzed in 58 replicates. During this routine period of the
study three kit lots of the Immulite Tg assay were used.
Linearity
In a linearity experiment a human serum pool with high Tg
concentrations was diluted stepwise (9+1 to 1+9) with a “low-
Tg pool”. The measurements were performed after equilibra-
tion of the diluted samples for one hour. The actual concentra-
tion of the high concentration sample was estimated by
extrapolation from the low concentration sample and the con-
centration measured in the 5+5 diluted sample. For each dilu-
tion step recoveries were calculated on the basis of observed
and expected concentrations.
Carry-over
For a carry-over investigation a sample with a very high Tg
concentration (11400 ng/ml) was repeatedly measured in di-
rect sequence with a sample of a concentration below 1 ng/ml.
Interference
Possible effects of typical interfering factors (bilirubin, hemol-
ysis, uremia, and lipemia) were tested by spiking experi-
ments: basal concentrations of Tg were measured in samples
containing high amounts of interfering factors and a recovery
test was performed in the same way as done routinely in
patients’ samples (Table 1). All samples were tested negative
for anti-Tg antibodies.
Cross-reactivity
To test for cross-reactivity of the assay with thyroxine, two cal-
ibrators of a thyroxine immunoassay (ORTHO Vitros ECi;
Neckargmünd, Germany, zero-calibrator and high-calibrator,
thyroxine, 144 µg/l) were analyzed for Tg with the Immulite as-
say.
Anti-Tg antibodies
To study the effect of anti-Tg antibodies, 56 sera of patients
with thyroid carcinoma were screened using the DPC-Immu-
lite Anti-Tg assay to obtain antibody-containing samples; in
these samples Tg was measured with the Immulite Tg assay
and for comparison with the BRAHMS Tg assay including re-
covery tests. Additionally, stepwise dilutions of the anti-Tg
antibody containing high serum pool of the imprecision study
with system diluent were prepared and measured with both
assays; in this experiment the actual Tg concentration was
calculated by extrapolation from the 1+1 dilution with a nor-
mal anti-Tg antibody negative serum.
Method comparison
For a method comparison study, 383 consecutive serum sam-
ples of 303 patients with thyroid carcinoma were used that
were routinely sent for monitoring of surgical and radioiodine
therapy. Sera were analyzed within 24 h with the Immulite Tg
assay and the BRAHMS LUMItest Tg using a spiking recovery
test in each sample. For analysis of the paired results of the
two assays regression analysis according to Passing and Ba-
block (8) was performed and Kendall’s tau and Pearson’s coef-
ficient of correlation were calculated. Additionally, a bias plot
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Tab. 1 Technical characteristics of the DPC Immulite Tg assay and the BRAHMS LUMItest Tg assay.
DPC Tg Immulite® assay BRAHMS LUMItest® Tg assay
Antibodies Monoclonal mouse-Ab (bead), luminescent- Two monoclonal mouse-Ab (fixed on coated tube,
substrate-labeled second polyclonal sheep-Ab and luminescence labeled)
Calibration Predefined master-calibration, two-point 8 standards in double determination
adjustment in fourfold determination after (0.2 – 1000 ng/ml) in each series
14 days
low adjustor:
<0.2 ng/ml, 146447 counts
high adjustor:
26.9 ng/ml, 2815391 counts
Time to results 70 min, random-access; start-up time approx. approx. 24 h
5 min
Sample volume 50 µl 50 µl
Measuring range 0.2 – 300 ng/ml 0.2 – 1000 ng/ml
Recovery test 200 µl serum + 10 µl recovery sample, 50 µl serum + 10 µl Tg-recovery sample,
100 % corresponds to +45 ng/ml Tg; 100 % corresponds to +100 ng/ml Tg;
acceptable range 70 – 130 % acceptable range 70 – 130 %
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as described by Bland and Altman (9) was generated; in this
analysis the percentage difference of the results of each sam-
ple obtained on the two systems is plotted against the respec-
tive mean of both methods.
Interlaboratory survey
During the study, the laboratory participated in an interlabora-
tory quality control programme involving two lyophilized
samples which were measured both with the Immulite and
the BRAHMS Tg assays (INSTAND Institute, Düsseldorf, Ger-
many, survey 3/98).
Results
The results of the imprecision study are summarized in
Table 2; since the coefficient of variation was about 
10 % at a Tg concentration of 0.8 ng/ml results equal to
or below 0.5 ng/ml were assessed in the further evalua-
tion. The dilution experiment confirmed linearity of the
Immulite Tg assay over the whole measuring range
(0.2 – 300 ng/ml) with recoveries between 94 and 110 %.
No carry-over effect was observed at a Tg concentra-
tion of 11400 ng/ml. The two highest Tg concentrations
found during the evaluation were 256000 ng/ml and
76500 ng/ml; in neither sample a high-dose hook effect
was found. In the interference studies marked bilirubi-
nemia was associated with an impaired recovery of
spiked Tg (bilirubin 296 µmol/l, 45 %; bilirubin 176
µmol/l, 56 %).
Lipemic (triglycerides 10.7 mmol/l), uremic (creati-
nine 698 µmol/l), and hemolytic sera (free hemoglobin
40 µmol/l) showed acceptable recoveries between 80
and 89 %.
In thyroxine assay calibrator preparations a Tg con-
centration of 0.65 and 0.55 ng/ml was found in the zero-
and the high calibrator, respectively; a similar concen-
tration is found in the Immulite Tg diluent.
The “high Tg pool“ used for the imprecision study
that contained 180 IU/l  anti-Tg antibodies showed line-
arity of dilution both with the Immulite and the
BRAHMS assay. 
In the 57 sera screened for anti-Tg antibodies, signif-
icant antibody concentrations (>100 IU/l, manufac-
turer’s reference range) were found in four; results of
the Immulite and the BRAHMS Tg assay with the re-
spective recovery of these samples are given in Table 3. 
In the method comparison study using 383 sera of
patients with thyroid carcinoma, the median Tg con-
centration found with the Immulite assay was 24.7
ng/ml, and 16.1 ng/ml with the BRAHMS assay. Thirty-
nine samples had Tg concentrations above the meas-
uring range of the Immulite assay (>300 ng/ml) and 17
samples had to be diluted in the BRAHMS assay (>1000
ng/ml). Values within the measuring range of either as-
say (n=180) had a Kendall’s tau coefficient of correla-
tion of 0.890, and a Pearson’s coefficient of correlation
of 0.979 (Figure 1). Regression analysis according to
Passing and Bablok yielded the following equation: 
Tg Immulite = 1.6 x Tg BRAHMS – 0.1 ng/ml
(95 % confidence interval: 1.52 to 1.66 for slope, and
–0.60 to 0.62 for intercept). The bias plot according to
Bland and Altman (Figure 2) disclosed a mean percent-
age difference (Immulite Tg – BRAHMS Tg) of 39.0 %
(95 % confidence interval 33.0 % to 45.0 %, standard de-
viation (SD) 41 %). 
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Tab. 2 Inter-assay imprecision of the DPC-Immulite Tg assay.
Sample n Mean SD CV 1st half of the study 2nd half of the study
concentration Mean CV Mean CV
(ng/ml)
Pool low I 21 0.84 0.07 9.0 % 0.85 8.5 0.81 9.5
Pool low II 21 1.4 0.15 10.9 % 1.3 11.2 1.4 10.6
Pool normal 58 10.4 0.86 8.3 % 10.2 10.7 10.5 6.0
Pool high 21 215 14.3 6.7 % 215 6.6 215 6.8
Control low 58 9.8 0.79 8.1 % 9.6 9.9 10.0 6.5
Control high 58 62.1 3.8 6.1 % 62.2 6.9 61.9 5.3
Tab. 3 Comparative measurement and recovery of Tg in anti-Tg positive samples with the DPC-Immulite 
and the BRAHMS LUMItest Tg assay.
Sample Anti-Tg Tg Tg Recovery Recovery
antibodies Immulite BRAHMS Immulite BRAHMS
(U/l) (ng/ml) (ng/ml)
1 293 4.4 10.6 53 % 8.4 %
2* 180 226 218 50 % 75 %
3 161 7.9 10.2 91 % 96 %
4 129 <0.5 <1 94 % 96 %
5 115 956 784 120 % 75 %
* High pool of the imprecision study
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In 62 samples of the 383 sera of the method compar-
ison study, Tg was below the assumed respective func-
tional sensitivity in both assays (Immulite <0.5 ng/ml,
BRAHMS <1.0 ng/ml). In 96 cases Immulite Tg was
between 0.5 and 1.0 ng/ml, whereas BRAHMS Tg was
below 1.0 ng/ml. Forty-seven samples had an Immulite
Tg above 1.0 ng/ml and a BRAHMS Tg below 1.0 ng/ml;
the median Immulite Tg concentration of these sam-
ples was 1.7 ng/ml ranging up to 8 ng/ml.
Comparative follow-up investigation was possible in
59 patients with thyroid carcinoma (two follow-up sam-
ples in 46 cases, three in 11, more than three in two
cases). Agreement with respect to increase vs. de-
crease of serum Tg was found in 46 cases in which Tg
was detected in both assays. In 13 follow-up investiga-
tions (see Table 4) Tg was not detectable with the
BRAHMS assay in at least one sample. In patients no. 1
to no. 8 the first sample was drawn after thyroidectomy
and before routinely performed radioiodine therapy; in
these samples serum Tg was detected with the Immu-
lite assay but not with the BRAHMS assay. In all cases
in the respective subsequent sample drawn after de-
struction of residual thyroid tissue by radioiodine,
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Fig. 1 Method comparison between the DPC-Immulite and
the BRAHMS LUMItest Tg assay in patients with differentiated
thyroid carcinoma (note logarithmic scales; n=180; regression
analysis according to Passing and Bablok Immulite Tg = 1.6 x
BRAHMS Tg – 0.1 ng/ml; Pearson’s r=0.979)
Fig. 2 Method comparison between the DPC-Immulite and the BRAHMS LUMItest Tg assay in patients with 
differentiated thyroid carcinoma. Bias plot according to Altman and  Bland (9) (n=180).
Tab. 4 Tg concentrations during follow-up of patients with thyroid carcinoma who presented discordant results.
Patient Days Immulite Immulite BRAHMS BRAHMS
# between 1st result 2nd result 1st result 2nd result
sampling (ng/ml) (ng/ml) (ng/ml) (ng/ml)
1 5 0.9 119 <1 124
2 5 2.7 4.2 <1 1.7
3 5 1.2 4.3 <1 2.5
4 5 2.4 8.8 <1 9.0
5 5 2.2 5.9 <1 2.9
6 5 2.2 7.7 <1 4.6
7 5 1.0 1.6 <1 1.8
8 5 1.4 4.3 <1 5.7
9 200 30.7 3.1 13.3 <1
10 7 1.0 1.4 <1 <1
11 208 <0.5 1.3 <1 <1
12 5 0.7 2.3 <1 <1
13 230 14.5 1.7 6.5 <1
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serum Tg was detected in both assays. In the patients
no. 9 to no. 13 discordance was found with respect to
the detection of Tg, however, follow-up did not yet al-
low interpretation of the validity of either assay result. 
The median recovery of all samples in the method
comparison experiment (n=383) was 95 % (range 12-
189) in the Immulite assay, and 91 % (range 8-184) in
the BRAHMS assay. In 49 cases a recovery below 70 %
was found with the Immulite assay (12.9 %), and in 19
cases with the BRAHMS assay (5 %). Forty-five samples
had a recovery below 70 % in the Immulite assay and
with a recovery >70 % in the BRAHMS assay. The in-
verse pattern was found in five samples. Recoveries
below 70 % in both assays were found in only four
cases. 
In one patient with low percentage recovery in the
spiking study with the Immulite assay (recovery 39 to
49 %) but a normal recovery in the BRAHMS assay (85
to 127 %), a comparative follow-up with five measure-
ments over 8 months was possible. The results obtai-
ned using Immulite Tg were: (1) 3.6 ng/ml; (2) 5.2
ng/ml; (3) 6.4 ng/ml; (4) 4.3 ng/ml; (5) 4.0 ng/ml. The re-
spective results obtained using BRAHMS assay were:
(1) 3.5 ng/ml; (2) 6.7 ng/ml; (3) 7.4 ng/ml; (4) 3.9 ng/ml
(5) 2.9 ng/ml; thus the follow-up was well comparable.
In an interlaboratory survey the results of both as-
says were within the respective assay target concentra-
tion ranges. The results were as follows: 
Immulite Tg: sample A 1320 ng/ml observed, target
concentration 1130 ng/ml, acceptable range 621-1639
ng/ml (mean concentration of 1208 ng/ml in 16 partici-
pating laboratories; CV 7.1 %). Sample B 174 ng/ml
observed, target concentration 172, acceptable range
95-250 ng/ml (mean concentration of 170 ng/ml (CV
10.1) in all participants) 
BRAHMS Tg: sample A 526 ng/ml observed, target
concentration 533 ng/ml, acceptable range 373-693
ng/ml (mean concentration of 535 ng/ml in 28 partici-
pants; CV 6.8 %). Sample B 114 ng/ml observed, target
concentration 114 ng/ml acceptable range 79-148
ng/ml (mean concentration 114 ng/ml (CV 5.0 %) in all
participants).
Handling and practicability of the Immulite immunoas-
say system in the daily routine proved very satisfac-
tory; the highest possible throughput was 100 tests per
hour. No technical problems were noticed during the 
6 month period of the whole investigation. 
Discussion
As highest reliability in the lowest concentration range
is a key requirement for Tg determination, automation
of a Tg assay is a particular analytical challenge; we
therefore performed a minute evaluation of the first
mechanized Tg assay, the DPC-Immulite Tg assay.
The imprecision studies disclosed satisfactory coef-
ficients of variation in a human serum pool with a Tg
concentration below 1 ng/ml. Though imprecision of
Tg assays at low analyte concentrations is known to be
a critical issue (5), published data concerning commer-
cial assays are limited; usually normal-concentration
samples are used for imprecision studies (10, 11), the
number of series is small (12) and some reported data
lack details (13); different assay standardisations fur-
ther hamper comparison of imprecision data. To our
knowledge, reproducibility of Tg determination in the
low concentration range described here using the Im-
mulite Tg assay is superior to all published results of
other commercial Tg assays. 
Ensuring long-term stability of a Tg assay in the low-
est concentration range over years represents an on-
going challenge for all manufacturers; so far no quality
control material in the lowest concentration range is
commercially available. Therefore, quality control in
the routine use of a Tg assay should include human
serum pools covering this range to verify long-term
comparability of results.
The Immulite assay proved linear within the measur-
ing range up to 300 ng/ml. Compared to the BRAHMS
assay (up to 1000 ng/ml) this range is rather narrow.
Consequently, dilution was necessary in more cases
(Immulite 10 %, BRAHMS 4.4 % of all samples). Even
so, final results can be reported for a patient within one
day with the Immulite assay. We were able to exclude a
high-dose hook effect up to a concentration of 256000
ng/ml. In our experiments the assay did not show a
carryover phenomenon or significant interference
from lipemia, uremia and hemolysis, whereas in mark-
edly icteric sera low Tg recovery was found; such sam-
ples should be diluted before analysis. No cross-reac-
tivity with thyroxine was found; the Tg concentration
found in the thyroxine assay calibrator as well as in the
Tg system diluent obviously represents the Tg content
of a stripped human serum matrix as the concentra-
tions were equal in the low and the high thyroxine cali-
brator.
Anti-Tg antibody interference is a well recognized
problem of Tg determination (14). In our experiments
anti-Tg antibodies affected neither linearity nor preci-
sion of the Immulite Tg assay. In the comparative
measurement of anti-Tg antibody containing samples
with the Immulite and the BRAHMS assay, however, Tg
concentrations found with the Immulite assay were be-
low the BRAHMS results except for the sample with the
lowest anti-Tg antibody concentration and the “high
pool”; because of the considerable slope observed in
the method comparison study, this observation sug-
gests an effect of anti-Tg antibodies on the Immulite Tg
assay resulting in lower results. However, serum Tg
was detected in all patients in agreement with the
BRAHMS assay. 
In the Immulite assay, a higher percentage of sam-
ples with a recovery below 70 % was found compared
to the BRAHMS assay but the recommended condi-
tions of the recovery test differ considerably between
these two assays. In the recovery test as prescribed for
the Immulite assay a lower amount of Tg is spiked to a
larger sample volume; therefore this recovery test
must generally be assumed to be more sensitive to an-
alytical interferences. The comparative follow-up of
one patient with low recovery results in the Immulite
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assay and normal recovery in the BRAHMS assay re-
sulted in a good clinical agreement.
As no reference method for Tg determination is
available, interpretation of the validity of Tg results is
limited to the comparison with a clinically established
method such as the BRAHMS assay. We found a slope
of about 60 % between the Immulite and the BRAHMS
assay with higher values in the Immulite assay; the dif-
ferences were even more pronounced using lyophi-
lized interlaboratory survey material consistent with
different matrix effects in such samples. The observed
slope is explained by the use of different standard
preparations in the two assays; the Immulite assay is
calibrated with the  international Tg standard (CRM 457
(15,16)), whereas the BRAHMS assay uses an in-house
preparation. The use of the first certified standard prep-
aration for Tg will probably improve the commutability
of results between different Tg assays in the future (5,
17); generally patients’ Tg results should always be re-
ported together with the specification of the method
used. If methods are changed in an institution new in-
dividual baseline values must be established for
patients’ follow-up. The bias plot according to Altman
and Bland (9) shows that significantly lower Tg concen-
trations are obtained with the BRAHMS assay, particu-
larly in the concentration range below 3 ng/ml. This re-
sults in a poor commutability between the two assays.
However, the short-term follow-up of patients no. 1 to 8
shown in Table 8 before and after postoperative radio-
iodine thyroablation gives strong evidence that Immu-
lite Tg concentrations in the lowest concentration
range are in fact valid: in these patients detectable
serum Tg in both assays observed after radioiodine
therapy obviously resulted from destruction of residual
thyroid tissue. This implies that at the time of the first
postoperative sampling thyroid tissue was indeed
present, which was detected by the Immulite assay
(concentrations >0.5 ng/ml) but not by the BRAHMS as-
say (<1 ng/ml). However, the actual long-term prognos-
tic significance of concentrations between 0.5 and 1.0
ng/ml Immulite Tg in patients treated for thyroid carci-
noma is so far not defined.
We conclude that the automated Immulite Tg assay
meets the requirements for routine clinical use; impor-
tant advantages compared to the formerly used man-
ual method are increased sensitivity and precision in
the lowest concentration range, largely improved
workflow, improved turnaround time and the use of an
international standard preparation.
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